Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 5
Submit an article Journal homepage
690
Views
0
CrossRef citations to date
0
Altmetric
Review

Genetic Characterization to Improve Interpretation and Clinical Management of Hepatotoxicity Caused by Tyrosine Kinase Inhibitors

Colin F Spraggs1 Genetics, Quantitative Sciences, GlaxoSmithKline Research & Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, UKCorrespondence[email protected]
View further author information
,
Chun-Fang Xu1 Genetics, Quantitative Sciences, GlaxoSmithKline Research & Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, UKView further author information
&
Christine M Hunt2 Clinical Safety Systems, GlaxoSmithKline Research & Development, Research Triangle Park, NC, USA;3 Duke University, Durham, NC,USAView further author information
Pages 541-554 | Published online: 05 Apr 2013

References

  • Arora A , ScholarEM. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther.315 , 971–979 (2006).
  • Hartman JT , HapM, KoppHG et al. Tyrosine kinase inhibitors – a review on pharmacology, metabolism and side effects. Curr. Drug Metabol. 10 , 470–481 (2009).
  • Loriot Y , PerlemuterG, MalkaD et al. Drug insight: gastrointestinal and hepatic adverse events. Nat. Clin. Pract. Oncol. 5 , 268–278 (2008).
  • Chang J , RandM, BlumenthalG et al. FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors. J. Clin. Oncol. 29 , 3106 (2011).
  • Ostapowitz G , FontanaRJ, SchiotFD et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137 , 947–954 (2002).
  • Temple R . Hy‘s law: predicting serious hepatotoxicity. Pharmacoepidemiol. Drug Saf.15 , 241–243 (2006).
  • Lammert C , EinarssonS, SahaC et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 47 , 2003–2009 (2008).
  • Howell BA , YangY, KumarR et al. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J. Pharmacokinet. Pharmacodyn.39 , 527–541 (2012).
  • Uetrecht J . Immune-mediated adverse drug reactions. Chem. Res. Toxicol.22 , 24–34 (2009).
  • Aithal GP , RawlinsMD, DayCP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ319 , 1541 (1999).
  • Bjornsson E . Drug-induced liver injury: Hy‘s rule revisited. Clin. Pharmacol. Ther.79 , 521–528 (2006).
  • Senior JR . Monitoring for hepatotoxicity: what is the predictive value of liver “function” tests? Clin. Pharmacol. Ther.85 , 331–334 (2009).
  • Bjornsson E , OlssonR. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology42 , 481–489 (2005).
  • Andrade RJ , LucenaMI, FernandezMC et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 , 512–521 (2005).
  • Zimmerman HJ . Hepatotoxicty: the Adverse Effects of Drugs and Other Chmicals on the Liver. Lippincott Williams & Wilkins, Philadelphia, PA, USA (1999).
  • Andrade RJ , LucenaMI, KaplowitzN et al. Outcome of acute idiosyncratic drug-induced liver injury: long term follow-up in a hepatotoxicity registry. Hepatology 44 , 1581–1588 (2006).
  • Aithal PG , DayCP. The natural history of histologically proved drug-induced liver disease. Gut44 , 731–735 (1999).
  • Sharma SK , SinglaR, SardaP et al. Safety of three dfferent reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin. Infect. Dis. 50 , 833–839 (2010).
  • Nordstrom BH , FraemanKH, LuoW et al. Liver function test abnormalities in patients treated with small molecule tyrosine kinase inhibitors. Presented at: International Society for Pharmacoepidemiology Annual Meeting, Brighton, UK, 19–22 August 2010.
  • O‘Brien SG , GuilhotF, LarsonRA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348 , 995–1004 (2003).
  • Singer JB , ShouY, KantarjianHM et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia21 , 2311–2315 (2007).
  • Bonvin A , MesnilA, NicoliniFE et al. Dasatinib-induced acute hepatitis. Leuk. Lymphoma 49 , 1630–1632 (2008).
  • Carlini P , PapaldoP, FabiA et al. Liver toxicity after treatment with gefitinib and anastrazole: drug-drug interactions through cytochrome P450? J. Clin. Oncol. 35 , e60–e61 (2006).
  • Ho C , DavisJ, AndersonF et al. Side effects related to cancer treatment: CASE 1. Hepatitis hollowing treatment with gefitinib. J. Clin. Oncol. 23 , 8531–8533 (2005).
  • Shepherd FA , PereiraJR, CiuleanuT et al. Erlotinib in previously treated non-small cell lung cancer. N. Engl. J. Med. 353 , 123–132 (2005).
  • Arora A . Erlotinib-induced hepatotoxicity – clinical presentation and successful management: a case report. J. Clin. Exp. Hepatol.1 , 38–40 (2011).
  • Llovet JM , RicciS, MazzaferroV et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359 , 378–390 (2008).
  • van Hootegem A , VerslypeC, van Steenbergen W. Sorafenib-induced liver failure: a case report and review of the literature. Case Rep. Hepatol.2011 , 1–4 (2011).
  • Mueller EW , RockeyMI, RashkinMC. Sunitinib-related fulminant hepatic failure: case report and review of the literature. Pharmacotherapy12 , 1066–1070 (2008).
  • Sternberg CA , DavisID, MardiakJ et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28 , 1061–1068 (2010).
  • Goodman V , WangQ, PanditeL et al. Incidence and management of hepatic toxicity in pazopanib-treated patients. Ann. Oncol. 21(Suppl. 8) , viii282 (2011).
  • Moy B , RappoldE, WilliamsL et al. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. J. Clin. Oncol. 27 , 1043 (2009).
  • Kaplowitz N . Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Dis.4 , 489–499 (2005).
  • Tujios S , FontanaRJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat. Rev. Gastroenterol. Hepatol.8 , 202–211 (2011).
  • van Cutsem E , NowackiM, LangI et al. Randomized Phase III study of irinotecan and 5FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J. Clin. Oncol. 25 , S164 (2007).
  • Srinivasan S , ParsaV, LiuCY et al. Trastuzumab-induced hepatotoxicity. Ann. Pharmacother. 42 , 1497–1501 (2008).
  • Munoz A , CarreraS, FerreiroJ et al. Reversible liver toxicity with adjuvant trastuzumab for localised breast cancer. Ann. Oncol. 18 , 2045–2046 (2007).
  • Pessaux P , PanaroF, CasnediC et al. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case–control study. Eur. J. Surg. Oncol. 36 , 575–582 (2010).
  • Geyer CE , ForsterJ, LindquistD et al. Lapatinib pus capecitabine for HER2 positive advanced breast cancer. N. Engl. J. Med. 355 , 2733–2743 (2006).
  • Johnston S , PippenJ, PivotX et al. Lapatinib combined with letrozole compared with letrozole and placebo as first line therapy for postmenopausal horemone receptor-positive metastatic breast cancer. J. Clin. Oncol. 27 , 5538–5546 (2009).
  • Blackwell KL , BursteinHJ, StornioloAM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28 , 1124–1130 (2010).
  • Moy B , GossPE. Lapatinib-associated toxicity and practical management recommendations. Oncologist12 , 756–765 (2007).
  • Spraggs CF , BuddeLR, BrileyL et al. Hyperbilirubinemia in lapatinib treated patients is associated with Gilbert‘s syndrome UGT1A1 polymorphism. Cancer Res. 69(Suppl. 24) , Abstract 1112 (2009).
  • Landis S , ChenC, ByrneJA et al. Assessing physician compliance to recommended liver function test monitoring guidance in patients with metastatic breast cancer using lapatinib. Presented at: the 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, CCIB Barcelona, Spain, 23–26 August 2012.
  • Polli JW , HumphreysJE, HarmonKA et al. The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine GW572016, lapatinib) disposition and drug interactions. Drug Metab. Disp. 36 , 695–701 (2008).
  • Castellino S , O‘MaraM, KochK et al. Human metabolism of lapatinib, a dula kinase inhibitor: implications for hepatotoxicity. Drug Metab. Disp. 40 , 139–150 (2011).
  • Teng WC , OhJW, NewLS et al. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol. Pharmacol. 78 , 693–703 (2010).
  • Takakusa H , WahlinMD, ZhaoC et al. Metabolic-intermediate complex formation of human cytochrome P450 3A4 by lapatinib. Drug Metab. Disp. 39 , 1022–1030 (2011).
  • Chan EC , NewLS, ChuaTB et al. Interaction of lapatinib with cytochrome P450 3A5. Drug Metab. Disp. 40 , 1414–1422 (2012).
  • Pauli-Magnus C , MeierPJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology44 , 778–787 (2006).
  • Sonpavde G , HutsonTE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep.9 , 115–119 (2007).
  • Hutson TE , DavidID, MachielsJP et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 28 , 475–480 (2010).
  • Xu CF , ReckBH, XueZ et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert‘s syndrome UGT1A1 polymorphism. Br. J. Cancer 102 , 1371–1377 (2010).
  • Goh BC , ReddyNJ, DandamudiUB et al. An evaluation of thr drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyeosine kinase inhibitor, using a modified cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin. Pharmacol. Ther. 88 , 652–659 (2010).
  • Xu C , XueZ, BingN et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann. Oncol. 23 , 2470–2471 (2012).
  • Bosma PJ , ChowdhuryJR, BakkerC et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1A1 in Gilbert‘s syndrome. N. Engl. J. Med. 333 , 1171–1175 (1994).
  • Balisteri WF , JansenP, KarpenSJ et al. Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference. Hepatology 42 , 222–235 (2005).
  • Sanna S , BusoneroF, MaschioA et al. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum. Mol. Genet. 18 , 2711–2718 (2009).
  • Bielinski SJ , ChalHS, PathakJ et al. Mayo genome consortia: a genotype–phenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin. Proc. 86 , 606–614 (2011).
  • Kang TW , KimHJ, JuH et al. Genome-wide association of serum bilirubin levels in Korean population. Hum. Mol. Genet. 19(18) , 3672–3678 (2010).
  • Johnson AD , KavousiM, SmithAV et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum. Mol. Genet. 18 , 2700–2710 (2009).
  • Aithal GP , WatkinsPB, AndradeRJ et al. Case definition and phenotype standardisation in drug-induced liver injury. Clin. Pharmacol. Ther. 89 , 806–815 (2011).
  • Green RM , FlammS. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology123 , 1367–1384 (2002).
  • Danoff TM , CampbellDA, McCarthyLC et al. A Gilbert‘s syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J. 4 , 49–53 (2004).
  • Lee JS , WangJ, MartinM et al. Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab. Pharmacogenet. Genomics 21 , 365–374 (2011).
  • Zucker SD , QinX, RousterSD et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl Acad. Sci. USA 98 , 12671–12676 (2001).
  • Rotger M , TaffeP, BleiberG et al. Gilbert syndrome and the development of antiretroviral therapy–associated hyperbilirubinemia. J. Infect. Dis. 192 , 1381–1386 (2005).
  • Li L , BacanuS, WhittakerJC et al. Disentangling baseline and on-treatment total bilirubin associations with UGT1A1*28. Presented at: 60th Annual Meeting of the American Society for Human Genetics, Washington, DC, USA, 2–6 November 2010.
  • Daly AK , DayCP. Genetic association studies in drug-induced liver injury. Semin. Liver Dis.29 , 400–411 (2009).
  • Phillips EJ , MallalSA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics11 , 973–987 (2010).
  • Andrade RK , RoblesM, UlzrrunE et al. Drug-induced liver injury. Pharmacogenomics 10 , 1447–1487 (2009).
  • Daly AK , DonaldsonPT, BhatnagarP et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet.41 , 816–819 (2009).
  • O‘Donohue J , OienKA, DonaldsonP et al. Co-amoxiclav jaundice: clinical and histological features and class II HLA association. Gut 47 , 717–720 (2000).
  • Lucena MI , MolokhiaM, ShenY et al. Susceptibility to amoxicillin–clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141 , 338–347 (2011).
  • Hetherington S , HughesAR, MostellerM et al. Genetic variation in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359 , 1121–1122 (2002).
  • Mallal SA , PhillipsEJ, CarosiG et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358 , 568–579 (2008).
  • Chessman D , KostenkoL, LethborgT et al. Human leukocyte antigen class I-restricted activation of CD8+ T-cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28 , 822–832 (2008).
  • Chung WH , HungSI, HongHS et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 428 , 486 (2004).
  • Ko TM , ChungWH, LinCH et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens–Johnson syndrome. J. All. Clin. Immunol. 128 , 1266–1276 (2011).
  • Xu CF , ReckBH, GoodmanVL et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J. Hepatol. 54 , 1237–1243 (2011).
  • Watkins PB , DesaiM, BerkowitzSD et al. Evaluation of drug-induced serious heaptotoxicity (eDISH): application of this data organisation approach to Phase III clinical trials of rivaroxiban after total hip or knee replacement surgery. Drug Saf. 34 , 248–252 (2011).
  • Allen KJ , GurrinLC, ConstantineCC et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358 , 221–230 (2008).
  • Forooghian F , DasB. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1α. Am. J.Opthalmol.144 , 761–768 (2007).
  • Danan G , BenichouC. Causality assessment of adverse reactions to drugs I: a novel method based on the conclusions of international consensus meetings: application to drug-indiced liver injuries. J. Clin. Epidemiol.11 , 272–276 (1993).
  • Andrade RJ , RoblesM, LucenaMI et al. Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin. Drug Saf. 8 , 709–714 (2009).
  • Spraggs CF , BuddeLR, BrileyLP et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol.29 , 667–673 (2011).
  • Kindmark A , JawaidA, HabronCG et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8 , 186–195 (2008).
  • Strautnieks SS , BymeJA, PawlikowskaL et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 134 , 1203–1214 (2008).
  • Kroetz DL , Pauli-MagnusC, HodgesLM et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1 multidrug resistance transporter) gene. Pharmacogenomics 13 , 481–494 (2003).
  • Kobayashi D , IeiriI, HirotaT et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. 33 , 94–101 (2005).
  • Furihata T , SatohN, OhishiT et al. Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin induced myopathy. Pharmacogenomics J. 10 , 185–193 (2009).
  • Jones EY , FuggerL, StromingerJL et al. MHC class II proteins and disease: a structural perspective. Persp. Nat. Rev. Immunol. 6 , 271–282 (2006).
  • Spraggs CF , ParhamLR, HuntCM et al. Lapatinib-induced liver injury characterized by class II HLA and Gilbert‘s syndrome genotypes. Clin. Pharmacol. Ther. 91 , 647–652 (2012).
  • Becquemont L . HLA: a pharmacogenomics success story. Pharmacogenomics11 , 277–281 (2010).
  • Bharadwaj M , IllingP, TheodosisA et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu. Rev. Pharmacol. Toxicol. 52 , 401–431 (2012).
  • Goss PE , SmithI, O‘ShaughnessyJ et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, Phase 3 trial. Lancet Oncol. 14 , 88–96 (2013).
  • Keam SJ . Dasatinib in chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. BioDrugs22 , 59–69 (2008).
  • Carlini P , PapaldoP, FabiA et al. Liver toxicity after treatment with gefitinib and anastrazole: drug–drug interactions through cytochrome P450? J. Clin. Oncol. 35 , e60–e61 (2006).
  • Munster PN , BrittenCD, MitaM et al. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin. Cancer Res. 13 , 1238–1245 (2007).
  • Feng B , XuJJ, MirelesR et al. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Science 108 , 492–500 (2009).
  • Escudier B , PortaC, BonoP et al. Patient preference between pazopanib and sunitinib: results of a randomised double-blind, crossover study in patients with metastatic renal cell carcinoma (PISCES study NCT 01064310). J. Clin. Oncol. 30 , 277S (2012).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.